HD17 for Intermediate Stage Hodgkin Lymphoma

Last updated: April 3, 2020
Sponsor: University of Cologne
Overall Status: Completed

Phase

3

Condition

Lymphoma

White Cell Disorders

Marginal Zone Lymphoma

Treatment

N/A

Clinical Study ID

NCT01356680
HD17
  • Ages 18-60
  • All Genders

Study Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Hodgkin Lymphoma

  • CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included)

  • large mediastinal mass (>1/3 of maximum transverse thorax diameter)

  • extranodal involvement

  • elevated ESR

  • 3 or more involved nodal areas

  • written informed consent

Exclusion

Exclusion Criteria:

  • Leucocytes <3000/µl

  • Platelets < 100000/µl

  • Hodgkin Lymphoma as composite lymphoma

  • Activity Index (WHO) >2

Study Design

Total Participants: 1100
Study Start date:
January 13, 2012
Estimated Completion Date:
March 23, 2020

Connect with a study center

  • 1st Dept. of Medicine, Cologne University Hospital

    Cologne,
    Germany

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.